Molecular cloning of CYP1A from the estuarine fish Fundulus heteroclitus and phylogenetic analysis of CYP1 genes: update with new sequences

Since we published a phylogenetic analysis of the CYP1A subfamily in 1995, several additional full-length sequences have been reported, including three members of an entirely new subfamily, CYP1B. Two avian sequences were recently published, so that CYP1A sequence data are now available from three of the five major vertebrate lineages. The two new branches that have been added to the CYP1 family tree significantly add to our understanding of P450 evolution. The inclusion of the CYP1Bs to the phylogenetic analysis allows us to root inferred trees. Addition of the avian CYP1As indicates that the CYP1A1/CYP1A2 duplication present in the mammalian lineage may have occurred after the divergence of birds and mammals. The number of fish species from which full-length coding regions of CYP1A genes have been sequenced has increased from four (trout, plaice, toadfish, and scup) to nine. These include CYP1A sequences from tomcod, butterflyfish, sea bream, sea bass, and the full-length sequence of CYP1A from the killifish Fundulus heteroclitus that is reported here. Phylogenetic analyses incorporating the new fish CYP1A sequences support our original conclusion that the fish CYP1As are monophyletic and indicate that the genes are evolving at very different rates in different species.     

双乙醛草酰二肼直接快速光度法测定食品中痕量铜

研究了双乙醛草酸二肼与铜的显色反应，建立了分光光度法直接测定铜的新方法。试验结果表明，在pH8．0－10．0范围内，Cu2 与双乙醛草酸二肼形成稳定的紫红色配合物。该配合物在540nm处有一最大吸收峰，其表明摩尔吸光系数为2．4×104，铜量在0－12mg／50ml范围内符合比尔定律。共存离子干扰，误差仅 2.00％。用于食品中痕量钢测定．结果准确、可靠。     

Structure of the repeating unit of acid polysaccharide from Alteromonas sp. 4MS17

An acidic polysaccharide from Alteromonas sp. 4MC17 is built up of trisaccharide repeating units containing D-glucose, D-mannose and D-galacturonic acid residues. On the basis of methylation studies, 1H and 13C NMR-spectroscopy data, including two-dimensional homonuclear correlation spectroscopy and nuclear Overhauser effects, the following structure was suggested for the polysaccharide repeating unit: -->4)-beta-D-Glcp-(1-->4)-beta-D-GalpA-(1-->4)-beta-D-Manp-( 1-->.     

一种考虑不同期合闸的行波合闸保护新方法

当线路末端故障时，行波在线路末端的反射情况比较复杂，反向电流行波的极性有可能与正向电流行波的极性相反，而此时测距结果又与线路无故障时相同。因此，会造成行波测距式与行波极性比较式合闸保护的不正确动作。根据行波的折、反射理论，分析出当线路无故障时正向电流行波仅在线路末端发生反射，且电流行波的反射系数为-1，而当线路存在故障时，正向电流行波将在故障点发生反射，无论故障是否在线路末端，电流行波的反射系数都不会是-1。根据这一特征，提出了一种新的行波合闸保护方法。从原理上保证了在各种情况下保护都可以正确动作，大量的电磁暂态仿真结果也证明了这一点。     

Selecting optimum density of lattice of blades of screw pump impeller

A method is proposed for calculating the optimum density of lattice of blades of screw pump impeller that ensures, for a given cavitation margin (inlet pressure), the first critical condition on the partial cavitation characteristic of the pump. The equations obtained can be used also to calculate the permissible cavitation margin of screw centrifugal and screw mixed-flow pumps as well as of stand-alone screw impeller, provided the geometric and operating conditions of the screw are given. __________ Translated from Khimicheskoe i Neftegazovoe Mashinostroenie, No. 6, pp. 29–33, June, 2007.     

C51嵌套汇编子程序在阻抗测试仪研制中的应用

C51嵌套汇编子程序，充分发挥了两种语言自的优势，介绍了C51调用汇编子程序的接品规则，并通过阻抗测试仪程序开发的例子予以详细说明。     

可膨胀尾管悬挂器技术及其应用

可膨胀管悬挂器(ELH)作为尾管固井、完井工艺中一项革新型工具,可以成功地解决常规悬挂器因其原理和结构特点带来的固井施工难题及重叠段固井质量差等问题,成为下一代悬挂器研究的重点。文中以实体膨胀悬挂器系统为例,介绍了其结构原理及应用情况。     

Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support

4-Hydroperoxycyclophosphamide (4-HC), a commonly used marrow-purging agent, is active against many tumors, but is also toxic to normal marrow progenitors. Amifostine (WR-2721) is a sulfhydryl compound with chemoprotectant activity. Preclinical studies using suspensions of bone marrow and breast cancer cells demonstrated that ex vivo treatment with amifostine followed by 4-HC resulted in protection of marrow progenitors, with no compromise in the antitumor effect of 4-HC. This fact stimulated the development of a clinical trial. Bone marrow was harvested from 15 poor-prognosis breast cancer patients and randomly assigned to ex vivo treatment with amifostine followed by 4-HC (amifostine + 4-HC), or treatment with 4-HC alone. High-dose chemotherapy was then administered followed by infusion of the purged autologous bone marrow support (ABMS). Leukocyte engraftment, defined as a white blood cell count > or = 1 x 10(9)/L, was achieved in an average of 26 days for patients whose marrow was purged with amifostine + 4-HC versus 36 days for patients whose marrow was purged with 4-HC alone (P = .032). The average number of platelet transfusions (12 v 29; P = .017) and days of antibiotic therapy (28 v 40; P = .012) were significantly less for patients whose marrow was exposed to amifostine + 4-HC, compared with 4-HC alone. Unpurged backup marrow fractions were infused into three patients whose marrow was purged with 4-HC alone, because of inadequate marrow recovery. None of the patients who received amifostine + 4-HC-purged marrow required a backup marrow fraction. Complete remissions were achieved in 83% of patients with measurable disease, with no difference between the two cohorts. Forty-three percent of patients remained alive and progression-free at a mean of 13 months posttransplant. There was no significant difference in the rate or pattern of relapse for patients whose marrow was purged with amifostine + 4-HC compared with those whose marrow was purged with 4-HC alone. Ex vivo treatment of marrow with amifostine significantly shortens the time to marrow recovery, thereby reducing the risk of myelosuppressive complications in breast cancer patients receiving high-dose chemotherapy and 4-HC-purged ABMS. Since supportive care requirements are also significantly decreased, amifostine may reduce the cost of such therapy.